SARS-CoV-2 vaccines in development

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Origin and evolution of pathogenic coronaviruses

Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

Comprehensive role of SARS‐CoV‐2 spike glycoprotein in regulating host signaling pathway

Banerjee, S., Wang, X., Du, S., Zhu, C., Jia, Y., Wang, Y., & Cai, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27820 · Cited by 21

Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein

Li, H., Cheng, C., Shi, S., Wu, Y., Gao, Y., Liu, Z., Liu, M., Li, Z., Huo, L., Pan, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114426 · Cited by 21

A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations

Kim, S. A., Kim, S., Kim, G. B., Goo, J., Kim, N., Lee, Y., Nam, G., Lim, S., Kim, T., Chang, K. H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116123 · Cited by 22

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Fathi, A., Dahlke, C., Krähling, V., Kupke, A., Okba, N. M. A., Raadsen, M. P., Heidepriem, J., Müller, M. A., Paris, G., Lassen, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31557-0 · Cited by 19

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast

Inchingolo, A. D., Malcangi, G., Ceci, S., Patano, A., Corriero, A., Vimercati, L., Azzollini, D., Marinelli, G., Coloccia, G., Piras, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158485 · Cited by 22

Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2

Micco, S. D., Rahimova, R., Sala, M., Scala, M. C., Vivenzio, G., Musella, S., Andreï, G., Remans, K., Mammri, L., Snoeck, R., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114857 · Cited by 21

Immune response induced by novel coronavirus infection

Sun, Y., Zou, Y., Wang, H., Cui, G., Yu, Z., & Ren, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.988604 · Cited by 20

Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern

Yahaya, A. A. A.-F. B., Khalid, K., Lim, H. X., & Poh, C. L. (2023) · Viruses · doi:10.3390/v15030624 · Cited by 20

Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals

Kottur, J., White, K. M., Rodriguez, M. L., Rechkoblit, O., Quintana‐Feliciano, R., Nayar, A., García‐Sastre, A., & Aggarwal, A. K. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011546 · Cited by 21

Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants

Cacciottolo, M., Li, Y., Nice, J. B., LeClaire, M. J., Twaddle, R., Mora, C. L., Adachi, S. Y., Young, M., Angeles, J., Elliott, K., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290046 · Cited by 20

The HLA-II immunopeptidome of SARS-CoV-2

Weingarten-Gabbay, S., Chen, D. W., Sarkizova, S., Taylor, H. B., Gentili, M., Hernandez, G. M., Pearlman, L. R., Bauer, M. R., Rice, C. M., Clauser, K. R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113596 · Cited by 23

Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants

Cui, L., Li, T., Xue, W., Zhang, S., Wang, H., Liu, H., Gu, Y., Xia, N., & Li, S. (2024) · Viruses · doi:10.3390/v16060900 · Cited by 18

Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography

Lerer, E., Oren, Z., Kafri, Y., Adar, Y., Toister, E., Cherry, L., Lupu, E., Monash, A., Levy, R., Dor, E., et al. (2021) · BioTech · doi:10.3390/biotech10040022 · Cited by 20

Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers

Trofin, F., Năstase, E. V., Iancu, L. S., Constantinescu, D., Cianga, C. M., Luncă, C., Ursu, R. G., Cianga, P., & Dorneanu, O. (2022) · Pathogens · doi:10.3390/pathogens11030286 · Cited by 22

Review—Recent Development of Detection Methods for Controlling COVID-19 Outbreak

Madurani, K. A., Suprapto, S., Syahputra, M. Y., Puspita, I., Masudi, A., Rizqi, H. D., Hatta, A. M., Juniastuti, J., Lusida, M. I., & Kurniawan, F. (2021) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/abe9cc · Cited by 19

A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection

Gan, E. S., Syenina, A., Linster, M., Ng, B., Zhang, S. L.-X., Watanabe, S., Rajarethinam, R., Tan, H. C., Smith, G. J. D., & Ooi, E. E. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105138 · Cited by 19

Mathematical modelling of SARS-CoV-2 infection of human and animal host cells reveals differences in the infection rates and delays in viral particle production by infected cells

Bernhauerová, V., Lisowski, B., Rezelj, V. V., & Vignuzzi, M. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110895 · Cited by 19

Acute liver failure after vaccination against of COVID-19; a case report and review literature

Sohrabi, M., Sobhrakhshankhah, E., Ziaei, H., Kachuee, M. A., & Zamani, F. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101568 · Cited by 19

Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model

Liu, K., Gong, Y., Huang, C., Huang, P.-N., Yu, K.-Y., Lee, H.-C., Lee, S.-C., Chiang, H.-J., Kung, Y.-A., Lin, Y., et al. (2022) · mSphere · doi:10.1128/msphere.00883-21 · Cited by 19

SARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology

Pack, S. M., & Peters, P. J. (2022) · Vaccines · doi:10.3390/vaccines10020236 · Cited by 19

A Review of Different Vaccines and Strategies to Combat COVID-19

Sabitha, S., Shobana, N., Prakash, P., Padmanaban, S., Sathiyasree, M., Saigeetha, S., Chakravarthi, S., Uthaman, S., Park, I., & Samrot, A. V. (2022) · Vaccines · doi:10.3390/vaccines10050737 · Cited by 29

Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation

Darmarajan, T., Paudel, K. R., Candasamy, M., Chellian, J., Madheswaran, T., Sakthivel, L. P., Goh, B. H., Gupta, P. K., Jha, N. K., Devkota, H. P., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20984-7 · Cited by 19

Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2

Huang, W., Chiem, K., Martínez‐Sobrido, L., & Lovell, J. F. (2022) · Pathogens · doi:10.3390/pathogens11091035 · Cited by 20

Identification of an immunodominant neutralizing epitope of porcine Deltacoronavirus spike protein

Chen, R., Wen, Y., Yu, E., Yang, J., Liang, Y., Song, D., Wen, Y., Wu, R. J., Zhao, Q., Du, S., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125190 · Cited by 19

Nanomaterials Used in the Preparation of Personal Protective Equipment (PPE) in the Fight against SARS-CoV-2

Luca, P. D., Macario, A., & Nagy, J. B. (2023) · Inorganics · doi:10.3390/inorganics11070294 · Cited by 18

A robust deep learning workflow to predict CD8 + T-cell epitopes

Lee, C. H.-J., Huh, J., Buckley, P. R., Jang, M., Pinho, M. P., Fernandes, R. A., Antanaviciute, A., Simmons, A., & Koohy, H. (2023) · Genome Medicine · doi:10.1186/s13073-023-01225-z · Cited by 21

Therapeutic Controlled Release Strategies for Human Osteoarthritis

Wang, D., Liu, W., Venkatesan, J., Madry, H., & Cucchiarini, M. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402737 · Cited by 24

Risk factors for delayed negative conversion of SARS-CoV-2 in patients with COVID-19 pneumonia: a retrospective cohort study

Mo, P., Deng, L., Liu, X., Gao, S., Liang, K., Luo, M., Chen, T., Song, S., Ma, Z., Chen, X., et al. (2020) · Epidemiology and Infection · doi:10.1017/s0950268820002940 · Cited by 19

A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates

Guo, C. M., Peng, Y., Lin, L., Pan, X., Fang, M., Zhao, Y., Bao, K., Li, R., Han, J.-B., Chen, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100448 · Cited by 20

Covalent coupling of Spike’s receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2

Berguer, P. M., Blaustein, M., Bredeston, L. M., Craig, P. O., D’Alessio, C., Elias, F., Farré, P. C., Fernández, N., Gentili, H., Gándola, Y. B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-03675-0 · Cited by 18

Affinity of anti-spike antibodies in SARS-CoV-2 patient plasma and its effect on COVID-19 antibody assays

Macdonald, P. J., Ruan, Q., Grieshaber, J. L., Swift, K. M., Taylor, R. E., Prostko, J. C., & Tetin, S. Y. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103796 · Cited by 19

Investigation and Comparison of Specific Antibodies’ Affinity Interaction with SARS-CoV-2 Wild-Type, B.1.1.7, and B.1.351 Spike Protein by Total Internal Reflection Ellipsometry

Plikusienė, I., Mačiulis, V., Juciutė, S., Maciulevičienė, R., Balevičius, S., Ramanavičius, A., & Ramanavičienė, A. (2022) · Biosensors · doi:10.3390/bios12050351 · Cited by 19

From mechanism to applications: Advanced microneedles for clinical medicine

Yang, Y., Sun, H., Sun, X. N., Wang, Y., Xu, F., Xia, W., Chen, L., Li, M., Yang, T., Qiao, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.04.025 · Cited by 22

Novel Small-Molecule Scaffolds as Candidates against the SARS Coronavirus 2 Main Protease: A Fragment-Guided in Silico Approach

Augustin, T. L., Hajbabaie, R., Harper, M. T., & Rahman, T. (2020) · Molecules · doi:10.3390/molecules25235501 · Cited by 18

Vaccination against COVID-19 and society’s return to normality in England: a modelling study of impacts of different types of naturally acquired and vaccine-induced immunity

Song, F., & Bachmann, M. O. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053507 · Cited by 17

Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays

Ismail, A. I. H. E., Shurrab, F. M., Al-Jighefee, H. T., Al‐Sadeq, D. W., Qotba, H. A., Shaar, I. A., Yassine, H. M., Abu-Raddad, L. J., & Nasrallah, G. K. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4934 · Cited by 18

Cutaneous reactions following CoronaVac COVID‐19 vaccination: a case series of six healthcare workers from a single centre

Akdaş, E., Öğüt, B., Erdem, Ö., Öztaş, M. O., & İlter, N. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17592 · Cited by 18

SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma

Itell, H. L., Weight, H., Fish, C. S., Logue, J. K., Franko, N., Wolf, C. R., McCulloch, D. J., Galloway, J., Matsen, F. A., IV, Chu, H. Y., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01298-21 · Cited by 18

Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore

Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19

Toward resilient food systems after COVID-19

Sperling, F., Havlík, P., Denis, M., Valin, H., Palazzo, A., Gaupp, F., & Visconti, P. (2021) · Current Research in Environmental Sustainability · doi:10.1016/j.crsust.2021.100110 · Cited by 25

Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal

Subedi, D., Pantha, S., Subedi, S., Gautam, A., Gaire, A., Sapkota, D., Sapkota, S., Kandel, M., Parajuli, A., Ghimire, H. C., et al. (2021) · Vaccines · doi:10.3390/vaccines9121448 · Cited by 19

Immunometabolism at the service of traditional Chinese medicine

Cui, H., Zhang, J., Cheng, X.-H., Zheng, J., Zhang, Q., Zheng, R., You, L., Han, D., & Shang, H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106081 · Cited by 18

Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

Benning, L., Klein, K., Morath, C. P., Bartenschlager, M., Kim, H., Buylaert, M., Reineke, M., Töllner, M., Nußhag, C., Kälble, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840136 · Cited by 18

Combination of chemistry and material science to overcome health problems

Karges, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.03.004 · Cited by 18

Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy

Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 18

Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids

Maldonado, E., Morales, S., Urbina, F., & Solari, A. (2022) · Vaccines · doi:10.3390/vaccines10040587 · Cited by 19

Oral SARS-CoV-2 Spike Protein Recombinant Yeast Candidate Prompts Specific Antibody and Gut Microbiota Reconstruction in Mice

Zhang, L., Yao, L., Guo, Y., Li, X., Ma, L., Sun, R., Xue-qing, H., Liu, J., & Huang, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.792532 · Cited by 18

Immunogenicity and safety of an inactivated SARS‐CoV‐2 vaccine in people living with HIV: A cross‐sectional study

Cai, S., Liao, G., Yu, T., Gao, Q., Zou, L., Zhang, H., Xu, X., Chen, J., Lu, A., Wu, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27872 · Cited by 18

Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies

Chung, W., Preclaro, I. A. C., Chung, W., & Wang, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061260 · Cited by 18

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine

Leung, N., Cheng, S. M. S., Martín-Sánchez, M., Au, N. Y. M., Ng, Y. Y., Luk, L. L. H., Chan, K., Li, J. K. C., Leung, Y. W. Y., Tsang, L. C. H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac458 · Cited by 17

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines

Zhang, B., Huo, J., Huang, Y., Teo, S. Y., Duan, K., Li, Y., Toh, L. K., Lam, K., & Xu, S. (2022) · Vaccines · doi:10.3390/vaccines10071057 · Cited by 17

Bivalent hemagglutinin and neuraminidase influenza replicon particle vaccines protect pigs against influenza a virus without causing vaccine associated enhanced respiratory disease

Brand, M. W., Anderson, T. K., Kitikoon, P., Kimble, J. B., Otis, N., Gauger, P. C., Souza, C. K., Kaplan, B. S., Mogler, M. A., Strait, E. L., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.042 · Cited by 18

Real-World Effectiveness of Four Types of COVID-19 Vaccines

Abdel‐Qader, D. H., Abdel-Qader, H., Silverthorne, J., Kongkaew, C., Meslamani, A. Z. A., Hayajneh, W. A., Alwahadneh, A. M., Hamadi, S., Abu-Qatouseh, L., Awad, R. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11050985 · Cited by 18

Positively Charged-Amylose-Entangled Au-Nanoparticles Acting as Protein Carriers and Potential Adjuvants to SARS-CoV-2 Subunit Vaccines

Fan, B., Gu, J., Deng, B., Guo, W., Zhang, S., Li, L., & Li, B. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05295 · Cited by 18

A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice

Tokunoh, N., Tamiya, S., Watanabe, M., Okamoto, T., Anindita, J., Tanaka, H., Ono, C., Hirai, T., Akita, H., Matsuura, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224634 · Cited by 18

Immunity testing against COVID-19 from blood by an IoT-enabled and AI-controlled multiplexed microfluidic platform

Bhuiyan, N. H., & Shim, J. S. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115791 · Cited by 19

Zoonosis and zooanthroponosis of emerging respiratory viruses

Khalil, A. M., Martínez‐Sobrido, L., & Mostafa, A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1232772 · Cited by 25

How does media coverage affect a COVID-19 pandemic model with direct and indirect transmission?

Thirthar, A. A., Jawad, S., Shah, K., & Abdeljawad, T. (2024) · Journal of Mathematics and Computer Science · doi:10.22436/jmcs.035.02.04 · Cited by 18

COVID-19 Variants and Vaccine Development

Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 20

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

Makdasi, E., Zvi, A., Alcalay, R., Noy-Porat, T., Peretz, E., Mechaly, A., Levy, Y., Epstein, E., Chitlaru, T., Tennenhouse, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109679 · Cited by 19

Temporal Associations of B and T Cell Immunity with Robust Vaccine Responsiveness in a 16-Week Interval BNT162B2 Regimen

Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111013 · Cited by 17

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines

Isaacs, A., Li, Z., Cheung, S. T. M., Wijesundara, D. K., McMillan, C. L. D., Modhiran, N., Young, P. R., Ranasinghe, C., Watterson, D., & Chappell, K. J. (2021) · Vaccines · doi:10.3390/vaccines9020071 · Cited by 18

Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infectionPreprint

Nahass, G. R., Salomon, R. E. A., Blacker, G., Haider, K., Brotherton, R., Teague, K., Yiu, Y. Y., Brewer, R. E., Galloway, S., Hansen, P. S., et al. (2021) · medRxiv · doi:10.1101/2021.08.22.21262168 · Cited by 20

SARS-CoV-2 virus: Vaccines in development

Huang, Q., & Yan, J. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.009 · Cited by 18

Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19

Desvaux, E., Hamon, A., Hubert, S., Boudjeniba, C., Chassagnol, B., Swindle, J., Aussy, A., Laigle, L., Laplume, J., Soret, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254374 · Cited by 18

A Novel High-Throughput Nanopore-Sequencing-Based Strategy for Rapid and Automated S-Protein Typing of SARS-CoV-2 Variants

Wagner, G. E., Totaro, M. G., Volland, A., Lipp, M., Saiger, S., Lichtenegger, S., Forstner, P., von Laer, D., Oberdorfer, G., & Steinmetz, I. (2021) · Viruses · doi:10.3390/v13122548 · Cited by 17

SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection

Khateeb, D. M., Gabrieli, T., Sofer, B., Hattar, A., Cordela, S., Chaouat, A. E., Spivak, I., Lejbkowicz, I., Almog, R., Mandelboim, M., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010242 · Cited by 16

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness

Al‐Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M. A., Alshukairi, A. N., Temsah, M.-H. A., Mutair, A. S. A., Rabaan, A. A., Tirupathi, R., & Gautret, P. (2022) · Infection · doi:10.1007/s15010-022-01759-1 · Cited by 17

Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants

Prakash, S. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102482 · Cited by 17

VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entry

Ding, S., Ullah, I., Gong, S. Y., Grover, J. R., Mohammadi, M., Chen, Y., Vézina, D., Beaudoin-Bussières, G., Verma, V. T., Goyette, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104528 · Cited by 18

Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults

Nakagami, H., Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Nakagami, F., Hamaguchi, S., Yoshida, H., Okuno, H., Yoshida, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10091427 · Cited by 18

Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine

O’Donnell, J. S., Isaacs, A., Jakob, V., Lebas, C., Barnes, J. B., Reading, P. C., Young, P. R., Watterson, D., Dubois, P. M., Collin, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.976968 · Cited by 17

A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants

Goyal, L., Zapata, M. R., Ajmera, K. M., Chaurasia, P., Pandit, R., & Pandit, T. (2022) · Cureus · doi:10.7759/cureus.29837 · Cited by 17

SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders

Khare, S., Niharika, N., Singh, A., Hussain, I., Singh, N. B., & Singh, S. C. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04181-3 · Cited by 16

Inhibitory activities of alginate phosphate and sulfate derivatives against SARS-CoV-2 in vitro

Yang, C. L., Li, D., Wang, S., Xu, M., Wang, D., Li, X., Xu, X., & Li, C. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.311 · Cited by 16

Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice

Sazegari, S., Niaki, M. A., Afsharifar, A., Niazi‎, A., Derakhshandeh, A., Vahdat, M. M., Hemmati-Dinarvand, M., & Eskandari, M. H. (2023) · Microbial Cell Factories · doi:10.1186/s12934-023-02043-z · Cited by 17

Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery

Ramli, S., Wu, Y. S., Batumalaie, K., Guad, R. M., Choy, K. W., Kumar, A., Gopinath, S. C. B., Sarker, M. M. R., Subramaniyan, V., Sekar, M., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11041000 · Cited by 16

Disulfide stabilization reveals conserved dynamic features between SARS-CoV-1 and SARS-CoV-2 spikes

Zhang, X., Li, Z., Zhang, Y., Liu, Y., Wang, J., Liu, B., Chen, Q., Wang, Q., Fu, L., Wang, P., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201796 · Cited by 16

Systemic Lupus Erythematosus and COVID-19

Pappa, M. B., Panagiotopoulos, A. G., Thomas, Κ., & Fanouriakis, A. (2023) · Current Rheumatology Reports · doi:10.1007/s11926-023-01110-z · Cited by 17

Design and Immune Profile of Multi-Epitope Synthetic Antigen Vaccine Against SARS-CoV-2: An In Silico and In Vivo Approach

Invenção, M. D. C. V., de Macêdo, L. S., de Moura, I. A., Santos, L. A. B. D. O., Espinoza, B. C. F., de Pinho, S. S., Leal, L. R. S., dos Santos, D. L., Marcos, B. D. F. S., Elsztein, C., et al. (2025) · Vaccines · doi:10.3390/vaccines13020149 · Cited by 17

Vaccine and vaccination as a part of human life: In view of COVID‐19

Megha, K. B., Nayar, S. A., & Mohanan, P. V. (2021) · Biotechnology Journal · doi:10.1002/biot.202100188 · Cited by 22

Inactivation of SARS-CoV-2 by deep ultraviolet light emitting diode: A review

Minamikawa, T., Koma, T., Suzuki, A., Nagamatsu, K., Yasui, T., Yasutomo, K., & Nomaguchi, M. (2021) · Japanese Journal of Applied Physics · doi:10.35848/1347-4065/ac19d1 · Cited by 18

Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants

Yin, R. M., Guest, J. D., Taherzadeh, G., Gowthaman, R., Mittra, I., Quackenbush, J., & Pierce, B. G. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009380 · Cited by 18

A novel ensemble fuzzy classification model in SARS-CoV-2 B-cell epitope identification for development of protein-based vaccine

Özger, Z. B., & Cihan, P. (2021) · Applied Soft Computing · doi:10.1016/j.asoc.2021.108280 · Cited by 17

Determinants of the Development of SARS-CoV-2 Anti-Spike Immune-Response after Vaccination among Healthcare Workers in Egypt

El‐Ghitany, E. M., Hashish, M. H., Farag, S., Omran, E. A. H., Farghaly, A. G., & Azzam, N. F. A. E. M. (2022) · Vaccines · doi:10.3390/vaccines10020174 · Cited by 16

SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection

Richardson, J. R., Götz, R., Mayr, V., Lohse, M. J., Holthoff, H., & Ungerer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266701 · Cited by 16

Envelope virus-mimetic nanovaccines by hybridizing bioengineered cell membranes with bacterial vesicles

Zhang, M., Wang, L., Liu, J., & Pang, Y. (2022) · iScience · doi:10.1016/j.isci.2022.104490 · Cited by 17

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions

Haq, H. N., Khan, H., Chaudhry, H., Nimmala, S., Demidovich, J., Papudesi, B. N., & Potluri, S. D. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.08.003 · Cited by 17

Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro

Pasquereau, S., Galais, M., Bellefroid, M., Pachón-Angona, I., Morot-Bizot, S., Ismaïli, L., Lint, C. M. V., & Herbein, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-24682-9 · Cited by 17

COVID-19 vaccination rate and protection attitudes can determine the best prioritisation strategy to reduce fatalitiesPreprint

Rodríguez, J., Patón, M., & Acuna, J. M. (2020) · medRxiv · doi:10.1101/2020.10.12.20211094 · Cited by 18

Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations

Vakili, B., Bagheri, A., & Negahdaripour, M. (2021) · Biologia · doi:10.1007/s11756-021-00866-y · Cited by 16

Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers

Wi, Y. M., Kim, S., & Peck, K. R. (2021) · Vaccines · doi:10.3390/vaccines9080931 · Cited by 16

Voice Sequelae Following Recovery From COVID-19

Arias, T. R., & Betancort, M. (2022) · Journal of Voice · doi:10.1016/j.jvoice.2022.06.033 · Cited by 16

Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface

Xing, H., Zhu, L., Wang, P., Zhao, G., Zhou, Z., Yang, Y. A., Zou, H., & Yan, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935573 · Cited by 16

Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting

Elkhatib, W. F., Abdelkareem, S. S., Khalaf, W. S., Shahin, M., Elfadil, D., Alhazmi, A., El-Batal, A. I., & El-Sayyad, G. S. (2022) · Virology Journal · doi:10.1186/s12985-022-01902-2 · Cited by 17

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study

Tang, L., Zhang, Y., Wang, F., Wu, D., Qian, Z., Zhang, R., Wang, A., Huang, C., Wang, H., Ye, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063919 · Cited by 16

Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants

Stauft, C. B., Selvaraj, P., D’Agnillo, F., Meseda, C. A., Liu, S., Pedro, C. L., Sangare, K., Lien, C. Z., Weir, J. P., Starost, M. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39090-4 · Cited by 17

Identification, characterization and expression analysis of circRNA encoded by SARS-CoV-1 and SARS-CoV-2

Niu, M., Wang, C., Chen, Y., Zou, Q., & Xu, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbad537 · Cited by 17

Understanding Mucosal Physiology and Rationale of Formulation Design for Improved Mucosal Immunity

Biswas, M., Nurunnabi, M., & Khatun, Z. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00395 · Cited by 16

Circular mRNA Vaccine against SARS-COV-2 Variants Enabled by Degradable Lipid Nanoparticles

Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Gao, S., Zhao, P., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20770 · Cited by 32

Viral Vaccines and Current Status of Vaccine Developing Studies Against Novel SARS Coronavirus-2

Keşli, R. (2020) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2020.84755

SARS-CoV-2 Vaccine Development: An Overview and Perspectives

Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40

Phase III Vaccines for SARS-CoV-2: A Review of Development and Available Data

Ehsan, H. S. A., Sana, M. K., Sarwar, A., Hanif, N., & Khan, S. R. (2020) · Internal Medicine Review · doi:10.18103/imr.v6i5.905

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Alturki, S. O., Alturki, S. O., Connors, J. R., Cusimano, G. M., Kutzler, M. A., Izmirly, A. M., & Haddad, E. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01880 · Cited by 80

Latest in COVID-19 Vaccine 'Candidates' Race

Atoum, M. F. M., Zreig, D. A., & Zreig, L. M. A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220818124416